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Background: Usual treatment regimens with vancomycin often fail to provide adequate
serum levels in patients with severe infections.
Methods: Retrospective analysis of vancomycin trough serum measurements. The follow-
ing parameters were calculated by Bayesian analysis: vancomycin clearance, distribution
volume, and peak estimated concentrations. The area under the concentration curve (AUC)
(total daily dose/24h clearance of vancomycin) was used to determine the effectiveness
of treatment through the ratio of AUC/minimum inhibitory concentration (MIC) above 400,
using MIC=1g/mL, based on isolates of Staphylococci in cultures.
Results: Sixty-one vancomycin trough measurements were analyzed in 31 patients.
AUC/MIC>400 was obtained in 34 out of 61 dosages (55.7%), but the mean vancomycin
dose required to achieve these levels was 81mg/kg/day. In cases where the usual doses were
administered (40–60mg/kg/day), AUC/MIC>400wasobtained innineout of 18dosages (50%),
in 13 patients. Trough serum concentrations above 15mg/L presented a positive predictive
value of 100% and a negative predictive value of 71% for AUC/MIC>400.
Conclusion: Higher than usual vancomycin doses may be required to treat staphylococcal
infections in children with oncologic/hematologic diseases. Since the best known predictorof efﬁcacy is the AUC/MIC ratio, serum trough concentrations must be analyzed in con-
junction with MICs of prevalent Staphylococci and pharmacokinetic tools such as Bayesian
analysis.
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Introduction
Childrenwith cancer suffer the effects of immune suppression
caused by chemotherapy and by the disease itself. Prolonged
hospitalizations, frequent use of broad-spectrum antibiotics,
the need for long-term central venous catheters, and loss
of mucous membrane and skin integrity also contribute
to elevated risk of severe infections.1 Among neutropenic
patients, 15% to 25% develop bloodstream infections and, fre-
quently, they also develop infections of the respiratory and
urinary tracts, skin, and digestive system.2 Available data
show that Gram-positive bacteria cause 45% to 70% of the
bloodstream infections in neutropenic patients. The most
commonly isolated Gram-positive bacteria are coagulase-
negative staphylococci and Staphylococcus aureus, besides
Enterococcus.3 Almost all Staphylococcus strains isolated from
cancer patients are methicillin-resistant, and vancomycin is
the drug of choice for these infections. Teicoplanin, a gly-
copeptide whose effectiveness is similar to vancomycin, still
has a limiteduse due tohigher cost. Newandexpensive agents
with proven efﬁcacy against staphylococci, such as linezolid,
quinupristine-dalfopristine, and tigecycline also have limited
data regarding use in children.4
Vancomycin exhibits a complex pharmacokinetics, with
time-dependent bactericidal effect and moderate post-
antibiotic effect. It also has poor tissue penetration, and some
authors question its effectiveness in severe infections.5,6 The
consensus is that the obtainment of serum free-vancomycin
levels four to ﬁve times the minimal inhibitory concentration
(MIC) or a ratio of area under curve (AUC) of concentration
versus time/MIC above 400 is essential to achieve bacterial
eradication and clinical success.7 For methicillin-resistant
Staphylococcus aureus strains with MIC above 2g/mL, van-
comycin is not effective; considering the binding to serum
proteins of around 50%, trough levels of vancomycin should
be 15 to 20g/mL to reliably eradicate strains with a MIC of
2g/mL. The trough level is the minimal serum concentration
obtainedwithin 30minutes to one hour before the subsequent
dose, after drug serum stabilization (usually after the fourth
dose). Only a fraction (20% to 30%) of the vancomycin serum
concentration can be obtained in pulmonary tissue, so higher
doses are required to treat pneumonia.4,8 Other sites, such
as bones, cardiac vegetations, and tissues around prosthetic
devices, also have limited penetration.9
The usual vancomycin regimens frequently fail to provide
minimal serum levels of 15g/mL. Kitzis and Goldstein ana-
lyzed serum concentrations in adults (n=1,737) who received
usual doses of 2 to 6 g/day. Adequate levels to treat susceptible
methicillin-resistant Staphylococcus aureus (MIC up to 2g/mL)
were obtained in 81% of the patients, but only in 20.9%
to treat intermediate-sensitivity strains (MIC 2–8g/mL). In
780 patients, levels under 10g/mL were observed 36 to
48hours after the beginning of treatment.10 Alternative reg-
imens which could optimize the pharmacodynamics have
been proposed, such as elevation of the intermittent doses
and continuous infusion.11 Administration of higher doses
can provide effective serum levels, but the risk of nephrotox-
icity may be unacceptable with doses higher than 4g/day in
adults.1212;16(4):361–365
The vancomycin ideal therapeutic regimen for cancer
patients has not yet been determined and has been poorly
studied. The aims of this study were to analyze the van-
comycin estimated clearance and obtained serum levels in
children and adolescents with cancer, in order to evaluate the
suitability of usual dosing regimens for this population.
Methods
This was a retrospective study, including onco-
logic/hematologic patients, hospitalized at the intensive
care unit of this hospital, or submitted to bone marrow trans-
plantation, who used vancomycin in the year 2010. The study
was approved by the institutional research ethics committee
(protocol number 1913/2010). Because of its retrospective
characteristics, the informed consent was waived.
Vancomycin was measured with a particle enhanced tur-
bidimetric inhibition immunoassay: free vancomycin in the
serum competes with particle-bound vancomycin for drug-
speciﬁc antibody binding sites, thereby inhibiting antibody-
mediatedparticle aggregation. The rate andamount of particle
aggregation are inversely proportional to the amount of
vancomycin present in the sample.13 Blood samples were
obtained one hour before the subsequent dose, in steady-
state, which is at least after the fourth dose of vancomycin.
Using anthropometric data and vancomycin trough measure-
ments, the following parameters were calculated by Bayesian
analysis: vancomycin clearance, distribution volume, and
peak estimated concentration. Calculations were made using
an open-source pharmacokinetics software (JPKD–College of
Pharmacy, Kaoshiung Medical University–Taiwan). The area
under the curve (AUC) of vancomycin concentration, deﬁned
as total daily dose/24h vancomycin clearance, was analyzed.
The effectiveness of the regimen was evaluated by obtain-
ing an AUC/MIC ratio above 400. The value of MIC used for
calculations was the mode (i.e., the most frequent value) of
all MICs obtained from isolated Staphylococcus strains in cul-
ture samples of study patients. MIC was determined by agar
diffusion or automated MIC (BD PhoenixTM Automated Micro-
biology System). The Statistical Package for Social Sciences
(SPSS) version 10.1 (Pearson’s correlation test and descriptive
statistics) and Microsoft Excel (linear regression and graphics)
softwares were used for statistical analysis.
Results
Sixty-one vancomycin serum levels were analyzed in 31
patients. The general characteristics, clearance values, and
vancomycin concentrations are depicted in Table 1. Diagnoses
of patients are shown in Table 2.
Coagulase-negative staphylococci were isolated from
seven blood cultures and in two skin wound cultures. S. aureus
was isolated from two blood cultures and in one tracheal aspi-
rate sample. Other staphylococci isolated from blood cultures
were S. epidermidis (2), S. hominis (1), and S. haemolyticus (2).
Of all isolates, only four were methicillin-sensitive. The MICs
observed ranged from 0.5 to 1.5, and the most frequent value
was 1g/mL, found in seven isolates. This was the mode value
used in the analysis of the AUC/MIC quotient.
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Table 1 – Characteristics of the pediatric oncology/hematology patients.
Age (mean, range) 7 years (2m–13y)
Gender (male-female) 14–17
Weight in kg (mean, range) 22 (5–62)
Vancomycin clearance (mean±SD, range) 0.18± 0.11 (0.067–0.48)
Distribution volume (mean±SD) 1.03± 0.12
Serum creatinine (mean±SD) 0.44± 0.18
Serum albumin 3.67± 0.51
Estimated creatinine clearance (mL/min, Schwartz, mean±SD) 136± 44.8
Measured vancomycin trough serum levels (mean±SD) 16.11± 11.3
Estimated peak vancomycin serum levels (mean±SD) 29.33± 11.6
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Fig. 1 – Linear regression of serum creatinine and
vancomycin clearance.SD, standard deviation.
AUC/MIC results >400 were obtained in 34 of 61 dosages
55.7%), but the mean vancomycin dose to achieve this
atio was 81mg/kg/day (range: 10–156mg/kg/day). When the
sual vancomycin dose was administered (40–60mg/kg/day),
UC/MIC>400 was obtained in nine of 18 dosages (50%), from
3 patients.
AUC/MIC>400 was observed on 11 occasions in which
he trough levels were below 15mg/L (18%). However, in all
nstances where levels were above 15mg/L, the AUC/MIC was
lways >400, i.e., trough levels above 15mg/L have a posi-
ive predictive value of 100% and a negative predictive value
f 71% for the population studied and at current rates of
acterial sensitivity to MIC of 1g/mL. The calculated van-
omycin clearance by Bayesian analysis presented a stronger
orrelation with serum creatinine levels (Pearson’s correlation
oefﬁcient: −0.67, p<0.0001) than with creatinine clearance
evels estimatedwith the Schwartz formula14 (Pearson’s corre-
ation coefﬁcient: 0.40, p = 0.001). Figs. 1 and 2 show the linear
djustment lines (simple regression). The best-ﬁt line equa-
ion of vancomycin clearance in relation to creatinine was:
ancomycin clearance= (−0.365× serum creatinine) + 0.3427.
his equation could predict the values of vancomycin clear-
nce using serum creatinine with a ±20% precision in 41%
of the analyzed cases. No signiﬁcant correlation between
Table 2 – Oncology/hematology diagnoses (n).
Acute lymphoblastic leukemia+bone marrow transplantation (2)
Acute lymphoblastic leukemia (6)
Acute myeloblastic leukemia (3)
Adrenal cortical carcinoma (1)
Astrocytoma (1)
B-cell lymphoma (1)
Botryoid rhabdomyosarcoma (1)
Brainstem primitive neuroectodermal tumor (2)
Burkitt lymphoma (1)
Craniopharyngioma (2)
Ependymoma (1)
Fanconi anemia+allogeneic BMT (1)
Forearm rhabdomyosarcoma (1)
Hepatoblastoma (1)
Infantile ﬁbrosarcoma (1)
Medullary aplasia +allogeneic BMT (1)
Medulloblastoma (1)
Neuroblastoma+Pepper syndrome (1)
Optic nerve glioma (1)
Oropharynx undifferentiated carcinoma (1)
Rhinopharynx carcinoma (1)albumin levels and vancomycin clearance or distribution vol-
ume was observed.
Two patients (6.4%) had increased creatinine levels above
50% with vancomycin doses higher than usual. The greatest
change was observed in an 8-year-old patient with baseline
creatinine of 0.4, which rose to 0.73 with a vancomycin dose
of 83mg/kg/d.0.6
0.5
0.4
0.3
y = 0.0009x + 0.0611
R2 = 0.1661
0.2
0.1
0
0.0 50.0 100.0 150.0
Calculated creatinine clearance
Va
nc
om
yc
in
 c
le
ar
an
ce
200.0 250.0
Fig. 2 – Linear regression of creatinine clearance estimated
with the Schwartz formula and vancomycin clearance.
i s . 20
r364 braz j infect d
Discussion
Piro et al. analyzed vancomycin serum levels in 56 onco-
logic patients, submitted to bonemarrow transplantation, and
observed that the number of patients with under-therapeutic
levels was signiﬁcantly higher than those who achieved ther-
apeutic levels. These authors concluded that higher doses are
needed in oncologic patients with normal renal function.15
This fact can be explained by what was observed in the
present patient sample, which demonstrated vancomycin
clearances and distribution volumes superior to those previ-
ously reported. Lamarre et al. described a mean clearance of
0.103 L/h/kg, in a population of 98 general pediatric patients,
with a mean distribution volume of 0.43 L/kg.16 The present
values were, respectively, 0.18 L/h/kg and 1.02 L/kg.
The proportion of patients in which vancomycin therapeu-
tic levels were obtained with usual doses was similar to that
reported in adults by Lepe et al. (50%).17
Vancomycin induces bacterial death in a time-dependent
manner, with amoderate post-antibiotic effect. The necessary
dose to achieve recommended serum levels can be extremely
high, with increasing possibility of nephrotoxicity.18 In an
effort to establish a mathematical model that could quickly
suggest the ideal dose for adults with malignant hematologic
diseases, Buelga et al. analyzed data from 215 patients with
1,004 serum dosages of vancomycin. It was observed that the
patient weight was strongly correlated with distribution vol-
ume, while creatinine clearance and the diagnosis of acute
mieloblastic leukemia inﬂuence vancomycin clearance. The
authors proposed the following general model to estimate
vancomycin clearance (Vclear): Vclear = 1.08× estimated cre-
atinine clearance. The equation for distribution volume (DV)
was: DV=0.98×weight (kg). This model was able to predict
vancomycin clearance with a precision of ±20% in 33% of
cases.19
In the present sample, the parameter that showed a better
correlation with vancomycin clearance was serum creati-
nine, and the model derived from the ﬁtting line was able
to predict the clearance in 41% of cases (similar to the 33%
found by Buelga et al.19), with a tendency to overestimate
the lower values. Estimating the creatinine clearance with the
Schwartz’s formula showed no utility. It must be observed
that Buelga’s model presented, according to the authors, at
least two times more precision than the normally utilized
nomograms. Pharmacokinetical Bayesian analysis can allow
individual adjustments and could be more useful than the
pure mathematical models. From a single serum measure of
creatinine and vancomycin at steady-state (at any moment
after the fourth dose and after the drug distribution phase, one
to two hours after the end of infusion), it is theoretically possi-
ble to estimate the ideal dose required to achieve the intended
trough levels.17 This approach could avoid the inconvenience
of raising the dose by trial and error and reduce the costs of
multiple measures and the risk of nephrotoxic suprathera-
peutic levels, but prospective studies are lacking. Because of
its complexity, Bayesian analysis demands speciﬁc softwares
to be accessible to clinicians. Some commercial options are
available, with moderate to high cost, and the JPKD software
is free.12;16(4):361–365
The highest doses used were relatively well tolerated, with
only 6.4% of patients having signiﬁcant elevations of serum
creatinine.
Conclusion
This study shows that higher than usual vancomycin doses
may be required to treat staphylococcal infections in children
with oncologic/hematologic diseases. Since the best known
predictor of efﬁcacy is the AUC/MIC ratio, serum trough lev-
els must be analyzed in conjunction with MICs of prevalent
Staphylococci and pharmacokinetic tools such as Bayesian
analysis.
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